Cinaciguat

Cinaciguat

Systematic (IUPAC) name
4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl) phenyl]methoxy}phenyl)ethyl]amino}methyl) benzoic acid
Clinical data
Routes of administration	intravenous (?)
Identifiers
CAS Number	329773-35-5
ATC code	none
PubChem	CID 9808022
IUPHAR/BPS	5168
ChemSpider	7983781
UNII	59K0Y58UAD
Chemical data
Formula	C36H39NO5
Molar mass	565.697 g/mol
SMILES c4ccccc4CCc3ccc(cc3)COc1ccccc1CCN(CCCCC(O)=O)Cc2ccc(C(=O)O)cc2
InChI InChI=1S/C36H39NO5/c38-35(39)12-6-7-24-37(26-30-19-21-33(22-20-30)36(40)41)25-23-32-10-4-5-11-34(32)42-27-31-17-15-29(16-18-31)14-13-28-8-2-1-3-9-28/h1-5,8-11,15-22H,6-7,12-14,23-27H2,(H,38,39)(H,40,41) Key:WPYWMXNXEZFMAK-UHFFFAOYSA-N
(what is this?)  (verify)

Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure.

Mechanism of action

Cinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide. This increases biosynthesis of cyclic GMP, resulting in vasodilation.^[1]

See also

• Riociguat, another drug stimulating sGC, but with a different mechanism
• PDE5 inhibitors act further downstream in the nitric oxide signalling pathway, reducing cyclic GMP degradation.

References

1. Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009